Member Info for Brighty1

Yes, this is really big news regarding the April 10th AACR presentation. What's not to like about a title that says: "The study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell lines". Thanks for posting it. Great find. The conclusion is most encouraging "The combination of SRA737 and adavosertib warrants further evaluation for the treatment of selected TP53 mutated cancers". A good week for Sareum investors with this and the dexamethasone news. Hopefully we are nearing the end game. Good luck, Brighty

Extraordinarily exciting times ahead for Webis, especially when you read our Chairman's statement in the "Strategic opportunities and Outlook" section of the Webis Annual Report and Financial Statements. It doesn't get much better than this if you are a long term share holder:

"USA regulated gaming is seen as the hottest subject at present in global gaming, and something of a gold rush both in the USA and, indeed, internationally. Non-USA and certain European companies are experiencing severe regulatory issues, as well as margin problems, and appear almost desperate to be a part of the developments in the USA. As a result, it should come as no surprise that WatchandWager continues to be courted by large corporations, and indeed smaller operations with a view to software deals, strategic alliances, mergers or even outright acquisition opportunities. Principally led by our Managing Director, the Board assesses each opportunity on a case-by-case basis. It should be noted in the majority of instances, the Board takes the view that "they need us more than we need them" and we continue to protect our USA licensed presence as a core asset. We are very aware of the increased consolidation in the industry and the economies of scale of strategic partnerships and will keep shareholders aware of any meaningful strategic developments with the Group, most likely in the USA, but possibly with international partnerships" - Denham Eke, Chairman

It is becoming clear from B90's rise from 4.58p to 38p last week that Webis could follow suit and multi bag quite easily to 40p in the run up to sports betting being given the OK next year in California or M&A activity in the sector or of course a takeover of Webis. B90's share price gain is a superb reminder of what could happen here.

Good luck, Brighty

I'm not sure that it would be "desperate" or "tenuous" to communicate a possible winning formula that prevents Covid. On the contrary it is in fact very positive news for Sareum (and its share holders). Indeed, this exact point was reinforced in the most recent Quote Data profile about Sareum in the "Investment Summary" (June 25, 2020). it stated:

"• Sareum’s investment case centres on the development and out-licensing of two preclinical-stage TYK2/JAK1 inhibitors for autoimmune disease and cancer. Sareum is also one of a small number of companies with a licensable TYK2 inhibitor programme. A large, randomised study of dexamethasone in COVID-19-related cytokine storm has shown the corticosteroid to reduce mortality in ventilated COVID-19 patients and those receiving oxygen. This supports the hypothesis that suppressing this undesirable inflammatory response can improve patient outcomes".

The full background can be found at:

https://quoteddata.com/research/sareum-holdings-potential-strategy-covid19/

An encouraging day for Sareum investors. Good luck, Brighty

Fantastic breaking news that could and should be exploited by Sareum regarding Dexamethasone, which is being hailed today as a lifesaver for over 1 million Covid patients in news out just now, see link below.
Sareum, as most long term holders here will know, has been trialling itsTYK2 in combination with dexamethasone. Some of you will recall that Tim Mitchell and Stephen Parker stated via RNS “The Sareum compound as a single agent was well tolerated and there was no change in tolerability when combined with dexamethasone”. This is fabulous for Sareum investors especially if this forms part of the Covid trial because if it does Sareum has already been able to demonstrate positive results with its TYK2 and dexamethasone. Come on Tim and John lets here more on this. Our results week just became even more interesting. Good luck, Brighty
https://news.sky.com/story/covid-19-dexamethasone-may-have-saved-lives-of-1-million-covid-sufferers-says-nhs-12253895

It is also worth pointing out to newbies here what the Webis Chairman said in the recent news update about our prospects: "Your Board believes that our standing as a credible proven licensed operator across the USA continues to place us in a unique position. The USA is clearly the land of opportunity in relation to licensed forms of gaming, and increasingly the major operators in our sector are looking to the USA for increased revenue streams. This can only enhance our position for the benefit of shareholders. We also need to look to the future, and we are very aware that USA regulated gaming is seen as a very relevant subject at present in global gaming space. The likely acquisition of William Hill by a US based corporation is clear evidence of that, and we expect this trend to continue". - Denham Eke, Non-executive Chairman

Exciting times. Good luck, Brighty

If B90's share price can go from 4.58 to 38.81p in a few days then that bodes brilliantly for Webis based on the value of our licences. Good luck, Brighty

4.5p to over 30p in 2 days for B90. So, just imagine where Webis' share price is heading based on the value of our licences if we receive a takeover bid or California announce an updated plan of its legislation. 30p+ a share for Webis would be cheap.....Good luck, Brighty

Plus don't forget that Webis extended its California licence until May 2025 with an option to 2030. A very smart move. I've been looking at the legislation discussions from California last year and it has been proposed that new entrants will have to pay $10 million dollars as a fee for a licence where as existing operators (such as Webis) will have their fees halved. This is making Webis even more attractive to the big players in my opinion re a takeover. Our share price & Mcap is very small indeed considering the value of the licences. Exciting times. Good luck, Brighty

Yes, Tekcapital currently owns approximately 17.8% (10.5m shares) of Belluscura which is now going to increase to 17.1m shares in Belluscura. Tekcapital had 30 days to exercise the options, that's what they have done and they now hold over 25% of Belluscura pre the IPO creating substantial value for TEK. This is positive news if you intend to hold TEK for the medium to long term. Good luck, Brighty

Yes and don't forget what Webis also said recently in an RNS:

"As a result, the company has had no shortage of informal offers from other interested parties in the space, specifically in the areas of software deals, strategic alliances and, at the operating company level only, mergers and even acquisition".

This could multi bag significantly in the run up to sports betting being given the OK next year in California or M&A activity in the sector or of course a takeover of Webis. Exciting times.

Good luck, Brighty

Avacta (up from 13p a year ago to 282p today) is a splendid example of the true value of Tim and John's business model about focusing on the IP. AVCT share holders must be delighted. Sareum's IP is our golden ticket and whilst a few people are starting to get a bit frustrated on here with the perceived slow progress (I've been here for over a decade so I am with you on that) all I would say is focus on the IP. That's where the mega licencing and takeover opportunities are for Sareum and where investors will make fabulous gains. Good luck, Brighty

Great photo story in the business section of The Times about ODX today.

"Omega Diagnostics said it expects the coronavirus test contract to result in substantial revenue growth
A contract secured by Omega Diagnostics to make coronavirus tests could be worth up to £374 million.

Details on the group’s agreement to provide manufacturing capacity for the Department of Health and Social Care (DHSC) were published as part of public sector disclosures. Omega announced last month it was going to produce tests for the government.

It pointed out yesterday that the £374 million was the maximum potential value of the contract and it could be lower, depending on how many tests were eventually purchased".

If you go back 12 months you will see that this is how it all started with NCYT with coverage in the mainstream media such as The Times, Daily Mail etc. It's happening now for ODX. £1 is just the start. Good luck, Brighty

All the pieces of the jigsaw are joining perfectly together for a rise to 100p soon with Gustavson estimating that Orinduik could hold 5,1 billion barrels (more than a billion-barrel increase from the previous estimate back in 2019 of 3,981), for Suriname. Plus with Rystad forecasting last week that this year would be a record one when it comes to offshore drilling in Guyana with an annual all time high of 16 wells expected, TLW is is the right place at the right time. Hopefully we will get an RNS soon to confirm the details of the Guyana extension until 2023 and success at Suriname. It's game on for 100p soon. Good luck, Brighty

"2020 was a major landmark in the Group's history. We achieved our goal of becoming capital self-sufficient and we now have more choices in how we deploy our resources" - CEO

Plus tangible net assets per share 199p (FY19: 181p per share).

Other key points:
Adjusted operating profit2 was 9% higher at £239m (FY19: £219m), as higher new business profit and improved in-force return has offset higher finance charges

IFRS profit before tax was £237m (FY19: £369m), as higher operating profit was more than offset by lower investment and economic profits, due to the property growth assumption change and the sale of an LTM portfolio

Retirement Income sales for 2020 up 12% to £2.1bn. Defined Benefit De-risking ("DB") sales were up 22% during the year to £1.5bn. Well positioned for attractive growth in 2021

Looking great here. Good luck, Brighty

At last, it's results day tomorrow for Just Group. Should be very interesting. Hoping to see the NAV at least match the 204p a share recorded at the end of June 2020 - over double the current (very under valued) share price. That will set things up perfectly for a re-rate to £2 per share this year. The curve ball of course, at some stage, could also be a takeover. 2021 is hotting up for Just investors. Good luck, Brighty

The UK Government's big Covid guns are certainly out in force praising ODX this evening. Health secretary Matt H via the Gov UK release and via Twitter Lord Bethell Minister of Innovation at dhscgovuk
@JimBethell We’re investing in 2m LFDs per week by end May from British firms @OmegaDiagnostic and @mologic to stop the spread of COVID-19. Investment in talent will help "build back better" & create 100s of jobs.
Looking very exciting hear. Good luck, Brighty

It's amazing to read on hear people deriding a small company that has won a massive manufacturing contract from the UK Gov't with a potential value of between £50 million to £374 million. It's time to celebrate. This is transformational whether ODX manufacture ANother's product or their own. There is money to be made, there is profit to be achieved and the future potential value of ODX has therefore been enhanced significantly. We just need the final piece of the jigsaw to slot in to place. i.e. the purchase orders. It is clear that there is a lot Colin wants to say but can't and he's therefore using Twitter to keep the momentum going until ODX can officially confirm order numbers. Patience is all that is required. Confirmation of a contract win of this magnitude is a huge step forward for Omega. Once the purchase orders are revealed the share price is going to soar. Good luck, Brighty

Check out the additional tantalising teaser tweet this morning:

"We'll make further statements as appropriate, considering that these production volumes are expected to result in substantial revenue growth for the new financial year".

It is pretty clear what he's been doing over the past few weeks.
* He's been telling us that ODX has been awarded a Gov't contract,
* he's been telling us that staff numbers have increased to 250,
* he's been telling us today that Omega has been awarded a contract with a potential value of £374 million and
* he's telling us just now that substantial revenue growth is coming.

"We're delighted to announce that UK Government has valued our 11 February contract, to provide manufacturing capacity for #COVID19 Lateral Flow Antigen Tests, at £374 million".

Says it all. Bring on the "Purchase order" RNS next and then a Novacyt share price rise awaits.

Good luck, Brighty

I like the wording in the Department of Health and Social Care confirmation of the £374million contract award to Omega. Details below. It states "Initial estimated total value of the contract/lot: £374,000,000".
The wording of "Initial" is most encouraging as it infers much more to come. A £374 million contract is pretty BIG news as far as I am concerned. I am happy to wait for the actual confirmation of the numbers but the contract award reads very well for ODX investors in my opinion and so does the following sentence in the ODX RNS today "the Company will make further statements given that these production volumes are expected to result in substantial revenue growth for new financial year". Happy days. Good luck, Brighty

V.2.3) Name and address of the contractor
OMEGA DIAGNOSTICS LIMITED

Omega House, Hillfoots Business Village, Alva

Clackmannanshire

FK12 5DQ

Country
United Kingdom

NUTS code
UK - UNITED KINGDOM

National registration number
SC107178

The contractor is an SME
Yes

five.2.4) Information on value of contract/lot (excluding VAT)V.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £374,000,000

Total value of the contract/lot: £374,000,000

Glen, to give you some feel good clarity about Sareum I would suggest that you simply look at our NED, Dr Michael Owen for a morale booster. He clearly knows what he's doing in our sector. Co founder of Kymab recently acquired by Sanofi for an upfront payment of approximately $1.1 billion plus he's NED at Avacta where he is the Senior Independent Director & Scientific Advisory Board Chairman. The AVCT share price is up from 13p a year ago to 256p today. This inspires me. Hopefully it will do the same for you. We are getting closer and closer to the big news if you look back at the previous 3 years of RNS'. Each piece of the SAR jigsaw, including our NED's, are joining up nicely. Looks to me as though 2021 is, finally, going to be a pivotal year for Sareum. Good luck, Brighty